Drug Trial Radar · NCT02120456
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
Last checked: Nov 20, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
224
Actual
Start
May 2014
Primary completion
May 2015
Study completion May 2015
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Apr 22, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Part 1: To identify Maximum Tolerated Dose (MTD) levels of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate the efficacy of LEO 43204 in two doses after once daily treatment for two consecutive days compared to vehicle
Conditions
- Actinic Keratosis
Interventions
LEO 43204Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Participants Experiencing Dose Limiting Toxicity (DLT) Based on Local Skin Responses (LSRs)Time frame: From Day 1 up to and including Day 8
- Part 2: Percent Reduction From Baseline in Actinic Keratosis (AK) CountTime frame: From baseline to Week 8
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
Omni Dermatology
Phoenix, Arizona
Torrance Clinical Research Institute Inc.
Lomita, California
Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.
San Diego, California
Dermatology Associates and Research
Coral Gables, Florida
Leavitt Medical Associates of Florida
Ormond Beach, Florida
Deaconess Clinic, Inc.
Evansville, Indiana
Hudson Dermatology, LLC
Evansville, Indiana
Indiana Clinical Trials Center
Plainfield, Indiana
DermAssociates, PC
Rockville, Maryland
Great Lakes Research Group, Inc.
Bay City, Michigan
The Dermatology Group, P.C.
Verona, New Jersey
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Pflugerville Dermatology Clinical Research Center, Inc.
Pflugerville, Texas
Kirk Barber Research
Calgary, Alberta, Canada
Enverus Medical
Surrey, British Columbia, Canada
Skin Care Centre
Vancouver, British Columbia, Canada
Winnipeg Clinic Dermatology Research
Winnipeg, Manitoba, Canada
UltraNova Skincare
Barrie, Ontario, Canada
Dermatrials Research Incorporated
Hamilton, Ontario, Canada
The Guenther Dermatology Research Centre
London, Ontario, Canada
SKiN Centre for Dermatology
Peterborough, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.